医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pall Opens New Life Sciences Centre of Excellence in Shanghai(China)

2013年10月16日 AM01:10
このエントリーをはてなブックマークに追加


 

SHANGHAI

Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today inaugurated the Pall Life Sciences Centre of Excellence (CoE) at its new Zhangjiang site in Shanghai in the People’s Republic of China. The new Centre of Excellence, which offers biopharmaceutical process solutions, technical and validation support as well as training, extends Pall’s local capabilities for its growing base of life sciences customers in the region.

“This year marks the 20th anniversary of Pall’s expansion into China. The opening of the Shanghai Life Sciences Centre of Excellence is another milestone in Pall’s development in China,” said Larry Kingsley, Chairman and CEO of Pall Corporation. “The new Centre of Excellence not only reinforces our commitment to investing in the region, but also makes it easier for customers in the area to do business with us.”

The new CoE is fully equipped with the most advanced capabilities for process demonstration, testing and validation. Customers also can consult with Pall experts about equipment selection, installation and adjustment.

Integrated with the CoE at the Shanghai facility is a branch office that serves both the company’s Life Sciences and Industrial customers. More than 200 employees work at the 8,600 m2 Shanghai facility, which provides filtration, separation and purification solutions for a range of industries. These include biopharmaceuticals, medical, food & beverage, process technologies, aerospace and microelectronics.

“China is an important market for Pall and long-term, favorable economic trends give us the confidence to continue development in the potentially high-growth region,” said Hang Gek Low, Vice President of Pall China. “The establishment of the Shanghai CoE enhances our ability to service customers in the area while enabling us to provide dedicated support for Chinese enterprises exploring overseas markets.”

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

About Pall China

Headquartered in Beijing, Pall Filter (Beijing) Co., Ltd. was founded in 1993 in Economic-Technological Development Area. It is a solely foreign-owned enterprise with branches or offices in Shanghai, Guangzhou, Chengdu, Changchun, Shijiazhuang and Jinan. The comprehensive sales and technical network is well established, enabling better and quicker service to customers all over China.

CONTACT

Pall Filter (Beijing) Co., Ltd.
No.12 Hongda Nanlu, Beijing
Economic-Technological Development Area (BDA),
Beijing 100176, P.R.
China
Tel: 86-10-87225588
or
Shanghai Branch, Pall Filter
(Beijing) Co., Ltd.
No.88 Shang Ke Road, Zhangjiang Hi-tech Park,
Pudong, Shanghai 201210,
P.R. China
Tel: 86-21-51915656
or
Media:
Vivien
Dong
Tel: 86-10-87225229
Vivien_Wei_Dong@ap.pall.com
or
Doug
Novarro
Tel: +1-516-801-9944
doug_novarro@pall.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin
  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A